Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
PARD3 encodes a member of the PARD protein family. Additionally we are shipping PARD3 Proteins (4) and many more products for this protein.
Showing 10 out of 63 products:
Human Polyclonal PARD3 Primary Antibody for EIA, WB - ABIN453777
Noda, Takeya, Ohno, Naito, Ito, Sumimoto: Human homologues of the Caenorhabditis elegans cell polarity protein PAR6 as an adaptor that links the small GTPases Rac and Cdc42 to atypical protein kinase C. in Genes to cells : devoted to molecular & cellular mechanisms 2001
Show all 2 references for ABIN453777
Human Polyclonal PARD3 Primary Antibody for FACS, IHC (p) - ABIN652622
Beausoleil, Jedrychowski, Schwartz, Elias, Villén, Li, Cohn, Cantley, Gygi: Large-scale characterization of HeLa cell nuclear phosphoproteins. in Proceedings of the National Academy of Sciences of the United States of America 2004
Par-3 plays an important role in the modulation of intestinal barrier function by regulating delivery of occludin as well as suppression of MLC phosphorylation.
HTT (show HTT Antibodies) is required for the apical localization of PAR3 (show F2RL2 Antibodies)-aPKC during epithelial morphogenesis in virgin, pregnant, and lactating mice.
Authors identify the cell polarity protein Par3, a negative regulator of neuronal differentiation, as a Smek1 (show SMEK1 Antibodies) substrate and demonstrate that Smek1 (show SMEK1 Antibodies) suppresses its activity.
Par3 (show F2RL2 Antibodies) (and protein kinase C zeta (show PRKCZ Antibodies)) are activated in neurons when binding to N2-proteoglygan.
Suggest that loss of Par3 (show F2RL2 Antibodies) promotes metastatic behaviour of ErbB2 (show ERBB2 Antibodies)-induced breast tumour epithelial cells by decreasing cell-cell cohesion.
Par3 (show F2RL2 Antibodies) is identified as a regulator of signaling pathways relevant to invasive breast cancer.
The nucleus of a myoblast moves rapidly after fusion towards the central myotube nuclei which is driven by microtubules and dynein/dynactin (show DCTN1 Antibodies) complex, and requires Cdc42 (show CDC42 Antibodies), Par6 (show PARD6A Antibodies) and Par3 (show F2RL2 Antibodies).
Data suggest that aPKC phosphorylates JAM-A (show F11R Antibodies) at S285 to regulate cell-cell contact maturation, TJ formation, and single lumen specification.
Brain-derived neurotrophic factor (BDNF (show BDNF Antibodies)) induces polarized signaling of small GTPase (show RACGAP1 Antibodies) (Rac1) protein at the onset of Schwann cell myelination through partitioning-defective 3 (Par3 (show F2RL2 Antibodies)) protein.
Report a willin(FRMD6 (show FRMD6 Antibodies))/Par3 (show F2RL2 Antibodies)-aPKC-ROCK pathway that controls epithelial apical morphology.
Knockdown of the polarity protein Par3 reversed the effects of Galpha13 (show GNA13 Antibodies) knockdown on cell-cell adhesion and proteolytic invasion in three-dimensional collagen.
Shp2 (show PTPN11 Antibodies) promotes metastasis of prostate cancer by attenuating the PAR3 (show F2RL2 Antibodies)/PAR6 (show PARD6A Antibodies)/aPKC polarity protein complex and enhancing epithelial-to-mesenchymal transition
study indicated a potential molecular basis for cell growth-promoting function of PARD3 by modulating the Hippo pathway signaling in response to cell contact and cell polarity signals
PAR3 (show F2RL2 Antibodies)-mutant proteins exhibit a relative reduction in the ability to mediate formation of tight junctions and actin-based protrusions and activate STAT3 (show STAT3 Antibodies) at cell confluence.
PAR3 (show F2RL2 Antibodies) and aPKC control the organization of the Golgi through CLASP2 (show CLASP2 Antibodies) phosphorylation.
Data show that increased partitioning defective 3 (Par-3 (show F2RL2 Antibodies)) expression is associated with distant metastasis and poor survival rates in patients with hepatocellular carcinoma (HCC (show FAM126A Antibodies)).
A cytoplasmic expression of PAR-3 (show F2RL2 Antibodies) is therefore implicated in worse clinical and pathological cancer features in clear cell renal cell carcinoma (show MOK Antibodies) and could be useful to identify patients with high-risk tumors.
The PAR (show JTB Antibodies) polarity complex of PARD3, PARD6, and an atypical protein kinase C (show PRKCZ Antibodies) (aPKC) regulate several aspects of neuronal migration.[review]
Our results suggest that PAR-3 (show F2RL2 Antibodies) has a role in the clinical aggressiveness of cell Renal Cell Carcinoma (show MOK Antibodies)
Pard3 mediates contact inhibition between neural crest cells and promotes timely myelin gene expression but is not essential for neural crest migration or myelination.
these results demonstrate a novel role of Par3 during neural crest migration, which is likely to be conserved in other processes that involve contact inhibition of locomotion such as cancer invasion or cell dispersion.
Pard3 and Rab11a (show RAB11A Antibodies) are necessary for lumen formation in the neural rod.
Brain-derived neurotrophic factor (BDNF (show BDNF Antibodies)) induces polarized signaling of small GTPase (show RACGAP1 Antibodies) (Rac1) protein at the onset of Schwann cell myelination through partitioning-defective 3 (Par3) protein.
Study demonstrates that the microtubule cytoskeleton gradually transitions from a radial to linear organization during neurulation and that microtubules function in conjunction with the polarity protein Pard3 to mediate centrosome positioning.
Agouti signaling (ASIP) genes exist in many species in lower vertebrates and were most probably present in early stages of vertebrate evolution.
Apical localization of ASIP in neuroepithelial cells involves the oligomerization domain CR1 (show TDGF1 Antibodies), the PDZ (show INADL Antibodies) domains, and the C-terminal portion of the protein.
This gene encodes a member of the PARD protein family. PARD family members interact with other PARD family members and other proteins\; they affect asymmetrical cell division and direct polarized cell growth. Multiple alternatively spliced transcript variants have been described for this gene.
partitioning-defective protein 3 homolog
, partitioning defective 3 homolog
, par-3 partitioning defective 3 homolog (C. elegans)
, atypical PKC isotype-specific-interacting protein
, ephrin-interacting protein
, atypical PKC-specific binding protein
, atypical PKC-specific-binding protein
, partitioning-defective 3 homolog
, three-PDZ containing protein similar to C. elegans PAR3 (partitioning defect)
, CTCL tumor antigen se2-5
, atypical PKC isotype-specific interacting protein
, par-3 family cell polarity regulator alpha
, par-3 partitioning defective 3 homolog